IQWiG’s Second Positive Halaven Decision Not Enough For Eisai
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai wants the G-BA to improve on its junior reimbursement partner IQWiG’s second decision on Halaven for breast cancer, which said the drug only offered limited additional benefit.